| |
|
|
Roundtable Discussion: Charles L Vogel, MD
and Julie A Plantamura, RN, MSN, FNPc
|
|
| |
|
|
|
| Track 1 |
Case discussion: A 52-year-old woman
with an ER-positive, PR-positive, HER2-
negative lobular carcinoma
and sentinel
node metastases |
|
| Track 2 |
Lobular carcinoma of the breast |
|
| Track 3 |
Utility of the Oncotype DX assay for
patients with node-negative disease who
have isolated tumor cells |
|
| Track 4 |
Identifying patients with a genetic predisposition
for breast cancer |
|
| Track 5 |
Role of oophorectomy for premenopausal
patients with hormone receptor-positive
breast cancer |
|
| Track 6 |
Management of bone health for patients on endocrine therapy |
|
| Track 7 |
Docetaxel combined with cyclophosphamide
(TC) in the adjuvant setting |
|
| Track 8 |
Tolerability of TC |
|
| Track 9 |
Psychosocial impact of chemotherapy-induced
alopecia |
|
| Track 10 |
Bonding among patients with breast
cancer and the benefits of support groups |
|
| Track 11 |
Assessing a child’s ability to understand
when a parent has cancer |
|
| Track 12 |
Providing support for children of breast
cancer patients |
|
| Track 13 |
Management of epiphora secondary to
docetaxel |
|
| Track 14 |
Impact of the Oncotype DX assay on
therapeutic decisions |
|
| Track 15 |
Benefit and selection of chemotherapy for
patients who are at high risk according to
the Oncotype DX assay |
|
| Track 16 |
Role of the Oncotype DX assay in the
TAILORx trial |
|
| Track 17 |
Spectrum of patient attitudes toward
adjuvant chemotherapy |
|
| Track 18 |
Clinical trials examining the use of the
Oncotype DX assay in node-positive
breast cancer |
|
| Track 19 |
Measurement of ER, PR and HER2
markers with the Oncotype DX assay |
|
| Track 20 |
Weight gain after breast cancer |
|
| Track 21 |
Reduction in recurrence risk secondary to
diet and exercise |
|
| Track 22 |
Relationship between ER status and
relapse rate in the Women’s Intervention
Nutritional Study |
|
| Track 23 |
Educating patients on the benefits of diet
and exercise |
|
| Track 24 |
Natural history of hormone receptor-positive
breast cancer and the risk of late
recurrences |
|
| Track 25 |
Unblinding of the MA17 trial and the
impact of delayed endocrine therapy |
|
| Track 26 |
Extended endocrine therapy in clinical
practice |
|
| Track 27 |
Management of arthralgias secondary to
aromatase inhibitors |
|
| Track 28 |
Patient compliance with long-term, oral
endocrine therapy |
|
| Track 29 |
Adherence to endocrine therapy in clinical
practice |
|
| Track 30 |
Indications for growth factor support with
adjuvant chemotherapy |
|
| Track 31 |
Case discussion: An 88-year-old woman
who developed metastatic disease
15 years after primary therapy for
ER-positive, PR-positive, node-positive
breast cancer |
|
| Track 32 |
Management of metastatic breast cancer
as a chronic disease |
|
| Track 33 |
First-line capecitabine for endocrine-resistant
metastatic disease |
|
| Track 34 |
Quality of life for patients with chronic
metastatic breast cancer |
|
| Track 35 |
Avoidance of premedications with
nanoparticle albumin-bound (nab)
paclitaxel |
|
| Track 36 |
Efficacy of nab paclitaxel versus standard
taxane therapy |
|
| Track 37 |
Tolerability of nab paclitaxel |
|
| Track 38 |
Median survival rates for patients with
Stage IV breast cancer |
|
